RxDoctor Payments Data

Robert Allen, MD

Family Medicine · Decatur, ALNPI 1215998430

Payments from drug & device makers

$1,093in general payments, 2019–2025

Across 41 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$191
  • AstraZeneca$152
  • Abbott$128
  • Novo Nordisk$103
  • Merck$92
  • Lilly USA, LLC$88
  • plus $338 from 9 others

What the payments were for

  • Food & beverage$1,093100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,093 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$5,250
Medicare patients
47
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$28,140
JanuviaSitagliptin Phosphate27$26,937
JardianceEmpagliflozin27$24,924
TrulicityDulaglutide17$21,796
JanumetSitagliptin Phos/Metformin Hcl20$20,120
EliquisApixaban22$18,603
XareltoRivaroxaban22$11,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,500
TrintellixVortioxetine Hydrobromide19$9,229
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,251
Esomeprazole Magnesium20$1,709
Atorvastatin Calcium140$1,487
Levothyroxine Sodium107$1,323
Pravastatin Sodium77$1,244
Fenofibrate36$1,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$92$47,05647 claims
Novo NordiskOzempic$103$28,14018 claims
Lilly USA, LLCTrulicity$88$21,79617 claims
PfizerEliquis$191$18,60322 claims
GSKTrelegy Ellipta$35$10,50017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →